Merck, GSK, J&J Embrace Targeted Sequencing for Drug Development and Biomarker Studies

Instead of focusing on whole-genome sequencing, which they all said was still too expensive, the three pharma companies are focusing on either specific genes, a portion of the exome, or the transcriptome.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.